Sugi Predict

Sugi Predict / Compounds / SCHEMBL1005092

SCHEMBL1005092

SCHEMBL1005092

CC1(C)OC(=O)[C@H](CC(=O)O)O1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 1/20 0.47
▸ APEX1 P27695 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HPGD P15428 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ BACE1 P56817 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ITGB3 P05106 1/20 0.31
▸ ITGB2 P05107 1/20 0.31
▸ ITGB1 P05556 1/20 0.31
▸ ITGAV P06756 1/20 0.31
▸ ITGA2B P08514 1/20 0.31
▸ ITGA5 P08648 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473047 1.00 GLS (0.47) GLSAPEX1KDM4ETSHRHTT
SCHEMBL200462 1.00 GLS (0.47) GLSAPEX1KDM4ETSHRHTT
Biphenyl SCHEMBL7177377 0.89 GLS (0.41) GLSAPEX1KDM4ETSHRHTT
SCHEMBL9460988 0.86 GLS (0.46) GLS
SCHEMBL18218788 0.85 GLS (0.47) GLSHTTSMN1; SMN2BACE1
SCHEMBL18914987 0.85 GLS (0.47) GLSKDM4EBACE1
SCHEMBL18219056 0.85 GLS (0.47) GLSHTTSMN1; SMN2BACE1
SCHEMBL23296774 0.83 GLS (0.46) GLSBACE1
SCHEMBL183678 0.83 GLS (0.46) GLSBACE1
SCHEMBL2280018 0.83 GLS (0.46) GLSBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1504002-B1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE BETA-AMINOKETONES AND OPTICALLY ACTIVE 1,3-AMINOALCOHOLS SANOFI AVENTIS DEUTSCHLAND (DE) 2012-12-19 — — EP claimed
CN-102617540-A Method for preparing (S)-3,6-dioxo-5,6-isopropylidene-5,6-dyhydroxyl hexanoic acid tert-butyl ester JIANGSU SHIMEIKANG PHARMACEUTICAL CO LTD 2012-08-01 — — CN claimed
US-7161008-B2 Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them Sanofi - Aventis Deutschland GmbH (DE) 2007-01-09 — — US claimed
US-20040030145-A1 Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-12 — — US claimed
US-12617782-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2026-05-05 — — US disclosed
EP-4594319-A1 BICYCLIC COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
WO-2025134071-A1 MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS SANOFI (FR) 2025-06-26 — — WO disclosed
WO-2025037940-A1 PYRAZOLE-1-CARBOXAMIDES AS RIP1 KINASE INHIBITORS BISICHEM CO., LTD. (KR) 2025-02-20 — — WO disclosed
US-20240150351-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024073559-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
US-20240034728-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2024-02-01 — — US disclosed
US-20230279170-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF KANSAS STATE UNIVERSITY RESEARCH FOUNDATION 2023-09-07 — — US disclosed
WO-1998039024-A1 SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS DARWIN DISCOVERY LIMITED (GB) 1998-09-11 — — WO disclosed
EP-0804430-A1 SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1997-11-05 — — EP disclosed
US-5656662-A TREATING OR PREVENTING ATHEROSCLEROTIC DISORDERS, INHIBITING INFLAMMATORY CYTOKINES THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1997-08-12 — — US disclosed
EP-0464817-B1 2,4-Dihydroxyadipic acid derivative KANEGAFUCHI CHEMICAL IND (JP) 1996-10-09 — — EP disclosed
US-5504107-A ANTICOAGULANTS, PREVENTING ATHEROSCLEROSIS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1996-04-02 — — US disclosed
WO-1995032194-A1 SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1995-11-30 — — WO disclosed
US-5214197-A 2,4-DIHYDROXYADIPIC ACID DERIVATIVE KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) 1993-05-25 — — US disclosed
EP-0464817-A1 2,4-Dihydroxyadipic acid derivative Kanegafuchi Chemical Industry Co., Ltd. (JP) 1992-01-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040030145-A1 Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them ORMDL3, OR10J3, BCAT2 GLS 2127/4885APEX1 3389/4885KDM4E 1494/4885
US-12617782-B2 Pyridazinones as PARP7 inhibitors PARP3, PARP2, PARP1 GLS 135/4885APEX1 456/4885KDM4E 2722/4885
US-20240150351-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 GLS 550/4885APEX1 4468/4885KDM4E 4157/4885
US-20240034728-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 GLS 1007/4885APEX1 122/4885KDM4E 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.